title: [Intensive chemotherapy for Burkitt lymphoma in HIV positive patients].
abstract: BACKGROUND
  Burkitt lymphoma has a low incidence, is highly aggressive, may be endemic, sporadic or associated with immunodeficiency and it has a high frequency of extranodal involvement. Overall and relapse free survival in HIV patients is 72 and 71% respectively. However, the current protocol in Chile considers a positive HIV serology as an exclusion criterion for intensive chemotherapy.
  
  
  OBJECTIVE
  To analyze the response to Burkitt lymphoma treatment among HIV positive patients.
  
  
  METHODS
  All HIV positive patients with a Burkitt lymphoma treated using PANDA protocol in a public hospital were analyzed.
  
  
  RESULTS
  Eight male patients aged between 25 and 43 years, 63% in stage IV, were analyzed. All patients received an intensified chemotherapy regime, three of them without Rituximab. Complete remission was achieved in 87%. One patient was refractory to treatment and one patient relapsed at 5 months and died. Overall and relapse free survival were 58 and 60% respectively. All patients had episodes of high risk febrile neutropenia, but it did not cause deaths.
  
  
  CONCLUSIONS
  In this group of HIV patients, intensive chemotherapy for Burkitt lymphoma had a high degree of effectiveness with a low relapse rate and high cure rate.
authors.forename: Bárbara
authors.initials: B
authors.lastname: Puga L
authors.forename: Katherinne
authors.initials: K
authors.lastname: Bustamante K
authors.forename: Javiera
authors.initials: J
authors.lastname: Molina E
authors.forename: Alejandro
authors.initials: A
authors.lastname: Andrade M
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002051:Burkitt Lymphoma / Q000188:drug therapy* / Q000209:etiology; D002677:Chile; D018572:Disease-Free Survival; D005260:Female; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D016896:Treatment Outcome; D055815:Young Adult